Generated by AI
Zura Bio Limited is a clinical-stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases. The company is building a multi-asset immunology pipeline centered on dual-pathway antibodies designed to address immune system imbalance and improve treatment options for patients with serious, underserved conditions. Its current programs include tibulizumab, torudokimab, and crebankitug, each targeting distinct immune pathways involved in inflammation and autoimmune activity. Zura Bio Limited concentrates on therapeutic areas such as hidradenitis suppurativa, systemic sclerosis, alopecia areata, and other immune-mediated disorders. By advancing differentiated antibody-based therapies, the company plays a specialized role in the biotechnology market as a developer of precision treatments for complex inflammatory diseases. Zura Bio Limited is headquartered in Henderson, Nevada.
Website1489 W. Warm Springs Road
Henderson, NV, 89014
United States
The latest articles about ZURA.
Analyst rates Zura Bio a Hold: illustrative $1.45 fair value implies 17% upside, insufficient ahead of TibuSURE's H1 2027 Phase 2 readout.
Summary of Nov 10's posts. Generated by AI.
Summary of Oct 27's posts. Generated by AI.
No summary yet.
Summary of Nov 10's posts. Generated by AI.
Investors talking about ZURA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.